GE Healthcare
GE gets behind Cerapedics and its i-FACTOR bone graft
GE Healthcare’s Q1 sales, profits slide
GE Healthcare (NYSE:GE) saw its sales and profits decline by single digits during the 1st quarter due to "market volatility.”
GE Healthcare posted profits of $570 million on sales of $4.20 billion for the 3 months ended March 31, for a bottom-line decline of 4.2% and a top-line slide of 2.1% compared with the same period last year.
GE Healthcare lands FDA nod for all-in-one CT
GE Healthcare’s (NYSE:GE) this week touted a new FDA win for its latest in CT scanner technology, saying the Revolution* CT^ is the 1st of its kind that’s right for "every clinical specialty."
DOD hands out $99.6 million in contracts to Hologic, GE, PositiveID | Medtech funding stories for the week of Apr. 7, 2014
GE Healthcare lands FDA clearance for Q.Clear imaging
GE Healthcare’s (NYSE:GE) won FDA clearance for its latest image reconstruction technology, the Q.Clear system for use with PET/CT scanning.
Hologic, GE, PositiveID land near $100M in Defense contracts
The U.S. Dept. of Defense handed out $99.6 million in contracts to a trio of device makers, providing for radiology systems, patient monitoring and airborne bio-threat detection for a variety of military and civilian agencies.
Medtech trends: The most talked about device makers in March 2014
Pentagon exercises $150M contract options with Philips, GE Healthcare
Love at first tweet: A look at medtech’s 1st forays into the social network
First impressions can be daunting primarily because they can have a long-lasting influence on a relationship, but what does it mean to make a 1st impression online?
Some of medtech’s biggest companies have made themselves Twitter regulators, but each had to start somewhere. Here are some of the industry’s 1st tweets:
Biomet puts itself back on public market | Medtech Wall Street news for the week of Mar. 10, 2014
Biomet announces IPO plans
March 7, 2014 by Brad Perriello
Biomet is planning to put itself back on the public market after a 7-year run under private equity ownership, the orthopedics giant said today.